ALDR Insider Trading Activity and SEC Form 4 Filings
ALDR insider trading summary
No open-market insider purchases or sales of Alder Biopharmaceuticals Inc (ALDR) have been reported on SEC Form 4 in the past 12 months.
Latest ALDR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 22, 2019 | Lundbeck A S H | 10% Owner | Buy | $0 (85,923,561 @ $0.00) |
| Sep 16, 2019 | Jeffrey T L Smith | Managing Director | Sell | $604K (32,728 @ $18.44) |
| Apr 25, 2019 | Randal Hassler | EVP, Pharmaceutical Ops. | Sell | $24K (1,738 @ $13.85) |
| Apr 25, 2019 | Erin Lavelle | Chief Operating Officer | Sell | $20K (1,434 @ $13.67) |
| Apr 25, 2019 | James B Bucher | EVP & General Counsel | Sell | $26K (1,897 @ $13.85) |
| Apr 25, 2019 | Larry Benedict | EVP and PAO | Sell | $24K (1,734 @ $13.65) |
| Dec 3, 2018 | Jeffrey T L Smith | Managing Director | Sell | $70K (5,044 @ $13.84) |
| Nov 1, 2018 | John A Latham | Chief Scientific Officer | Sell | $317K (23,683 @ $13.40) |
| Nov 1, 2018 | John A Latham | Chief Scientific Officer | Sell | $18K (1,319 @ $13.78) |
| Nov 1, 2018 | Jeffrey T L Smith | Managing Director | Sell | $68K (5,040 @ $13.42) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.